News & Events

The Firm is representing Centerview Partners LLC in its role as financial advisor to Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) in connection with Mallinckrodt plc’s (NYSE: MNK) definitive agreement to acquire Questcor for a combination of cash and equity valued at, based on Mallinckrodt’s pre-announcement closing price, approximately $5.6 billion. In the proposed transaction, shareholders of Questcor will receive $30.00 in cash and 0.897 shares of Mallinckrodt for each share of Questcor. According to the parties, the transaction is subject to customary closing conditions, including approval of the shareholders of both companies and Hart-Scott-Rodino clearance in the United States, and is currently expected to be completed in the third calendar quarter of 2014.

Questcor is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary, BioVectra Inc.  Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents.

The Simpson Thacher team includes Robert Spatt, Michael T. Holick and Paul Rodriguez.